Everything below concerns GHRH analog. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Animal hearts are widely consumed as a type of offal. As they are almost entirely muscle, they are high in protein. They are often included in dishes with other internal organs, for example in the pan-Ottoman kokoretsi. Chicken hearts are considered to be giblets, and are often grilled on skewers; examples of this are Japanese hāto yakitori, Brazilian churrasco de coração, and Indonesian chicken heart satay. They can also be pan-fried, as in Jerusalem mixed grill. In Egyptian cuisine, they can be used, finely chopped, as part of stuffing for chicken. Many recipes combined them with other giblets, such as the Mexican pollo en menudencias and the Russian ragu iz kurinyikh potrokhov. As heart is a hard-working muscle, it makes for "firm and rather dry" meat, so is generally slow-cooked. Another way of dealing with toughness is to julienne the meat, as in Chinese stir-fried heart. Beef heart is valued for its high meat quality and low price, being commonly disregarded in conventional meat pricing. It can be cut into steaks, comparable in quality to the more expensive cuts of meat from the same animal, though it is distinguished by a lack of a discernible grain. It was historically eaten in the United States as a cost-saving measure, but is today also eaten as an independently desirable ingredient. Beef heart may be grilled or braised. In the Peruvian anticuchos de corazón, barbecued beef hearts are grilled after being tenderized through long marination in a spice and vinegar mixture. An Australian recipe for "mock goose" is actually braised stuffed beef heart.
According to these principles, there must exist in space megastructures of great size, emitting a lot of energy and information, and existing for billions of years, while being compact enough to rapidly exchange large amounts of data between them. A supercivilization would thus create a technological structure of cosmic dimensions. As an example, Kardashev cites Freeman Dyson's megastructure, in the form of a sphere of several astronomical units in diameter. Other phenomena may indicate highly technological activities, such as artificially exploding stars or the changing of stellar orbits to store mass and energy. Giant molecular clouds also hold great potential for astroengineering. Kardashev even raises the possibility of a supercivilization reshaping the entire galaxy. Then he evokes the theoretical and mathematical possibility of the existence of a megastructure in the form of a disk rotating on itself at a constant angular velocity. According to him, the search for intelligent signals should be directed to the detection of such megastructures at the characteristic radiation (20 μm). Quasars or galactic centers can be excellent candidates to testify to the existence of a supercivilization since they emit strong infrared radiation, which indicates a solid structure. The astronomer advises to look for these objects in a wavelength range from a few microns to a few millimeters. Large intelligent structures can also be detected by the fact that they screen or reflect the surrounding radiation.
The expiry of the Malaysian New Economic Policy (NEP) in 1990 allowed Mahathir to outline his economic vision for Malaysia. In 1991, he announced Vision 2020, under which Malaysia would aim to become a fully developed country within 30 years. The target would require average economic growth of approximately seven per cent of gross domestic product per annum. One of Vision 2020's features would be to gradually break down ethnic barriers. Vision 2020 was accompanied by the NEP's replacement, the National Development Policy (NDP), under which some government programmes designed to benefit the bumiputera exclusively were opened up to other ethnicities. Mahathir highlighted that the policy would balance growth with addressing economic imbalances across regions and society. The NDP achieved one of its main aims — poverty reduction. By 1995, less than nine per cent of Malaysians lived in poverty, and income inequality had narrowed. Mahathir also introduced the Bangsa Malaysia policy, which aimed to facilitate greater representation of non-Malay ethnicities in Malaysia. Additionally, he popularised slogans like Malaysia Boleh (Malaysia Can) in his domestic politics. Mahathir's government cut corporate taxes and liberalised financial regulations to attract foreign investment. The economy grew by over nine per cent per annum until 1998, prompting other developing countries to emulate Mahathir's policies. Mahathir's bold economic initiatives propelled Malaysia to become the 17th largest trading nation globally.
==== Sexual reproduction ==== Seeds can be used for propagation of the plant or to create hybrids and can take five to eight years to produce flowering plants. Since interspecific cross-pollination occurs, overlapping wild populations can create natural hybrids.
Sources: en.wikipedia.org
In biochemistry, the glutamate–glutamine cycle is a cyclic metabolic pathway which maintains an adequate supply of the neurotransmitter glutamate in the central nervous system. Neurons are unable to synthesize either the excitatory neurotransmitter glutamate, or the inhibitory GABA from glucose. Discoveries of glutamate and glutamine pools within intercellular compartments led to suggestions of the glutamate–glutamine cycle working between neurons and astrocytes. The glutamate/GABA–glutamine cycle is a metabolic pathway that describes the release of either glutamate or GABA from neurons which is then taken up into astrocytes (non-neuronal glial cells). In return, astrocytes release glutamine to be taken up into neurons for use as a precursor to the synthesis of either glutamate or GABA.
It was hypothesized that the rapid mineralization processes required to preserve biomolecules degraded the organic matter, but either extracted or trapped chemical biomarkers in the clay mineral matrix during the early stages of mineralization, protecting those molecules from breakdown. Burial of samples in anaerobic sediments decreased biodegradation and increased preservation of biomarkers including sugiol. Sugiol was significantly more abundant in less oxidized samples. Additionally, the antimicrobial properties of sugiol could help to decelerate biodegradation of itself and other natural products by decreasing microbe driven breakdown.
=== Asprosin === Obesity is characterized by an overall increase in adiposity and, given that asprosin is secreted by adipose tissue, it is not surprising that both obese humans and mice show pathologically elevated levels of asprosin compared with control subjects. Patients presenting with insulin resistance and obesity have elevated serum levels of asprosin, and female patients with polycystic ovary syndrome have particularly high serum levels. Obese patients undergoing bariatric surgery for weight loss show decreased asprosin levels in serum after surgery. Asprosin-induced hyperphagia and hepatic glucose production could therefore be mechanisms that drive development of metabolic syndrome.
Casualty numbers have escalated significantly over time. According to a Stratfor report, the number of drug-related deaths in 2006 and 2007 (2,119 and 2,275) more than doubled to 5,207 in 2008. The number further increased substantially over the next two years, from 6,598 in 2009 to over 11,000 in 2010. According to data from the Mexican government, the death numbers are even higher: 9,616 in 2009, 15,273 in 2010, coming to a total of 47,515 killings between 2006 and January 2012. It is often not clear what deaths are part of the Mexican drug war versus general criminal homicides, and different sources give different estimates. Casualties are often measured indirectly by estimated total deaths from organized crime in Mexico. This amounts to about 115,000 people in the years 2007–2018. From 2018 to 2020, it was estimated that there were 11,400 reports of gang violence, and over 80% of the attacks targeted civilians, resulting in 13,000 related deaths during the period.
== Broadband == One of the first DIA approaches was a nozzle-skimmer dissociation method called shotgun collision-induced dissociation (CID). Fragmentation can be in the ion source of the mass spectrometer by increasing the nozzle-skimmer voltage in electrospray ionization. MSE is a broadband DIA technique that uses alternating low-energy CID and high-energy CID. The low-energy CID is used to acquire precursor ion mass spectra whereas the high-energy CID is used to obtain product ion information by tandem mass spectrometry.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.